Novartis, Cota Healthcare ink precision medicine collaboration deal
Expanding on a partnership first announced in 2016, Cota Healthcare and Novartis Pharmaceuticals Corporation have signed a multi-year agreement to work together toward improved clinical and cost outcomes for breast cancer patients.
Novartis will use Cota's cloud-based platform for evidence-based medicine to speed the development of therapies for breast cancer, using analytics and data visualization tools to identify the patients who would most benefit.
Cota's technology runs on its patented Cota Nodal Address system, which the company bills as a digital classification methodology than can stratify patients based on various personal and clinical factors. Patients with the same CNA can be considered "medically identical," according to Cota, and could benefit from similar treatments.
"Data and insight that comes directly from patient records – real-world evidence – is transforming how pharmaceutical and life science companies develop more precise, targeted therapies," said John Hervey, CEO of Cota, in a statement.
"Analyzing this data using CNAs is a critical factor in enabling healthcare companies to develop and target therapies that increase outcomes and lower the total cost of care," said Andrew Pecora, MD, Cota's founder and executive chairman.